Synergy between Trovafloxacin and Ceftriaxone against Penicillin-Resistant Pneumococci in the Rabbit Meningitis Model and In Vitro | Zendy

Philippe Cottagnoud | Zendy; Fernando Acosta | Zendy; M. Cottagnoud | Zendy; K Neftel | Zendy; Martin G. Täuber | Zendy

Open Access

Synergy between Trovafloxacin and Ceftriaxone against Penicillin-Resistant Pneumococci in the Rabbit Meningitis Model and In Vitro

Author(s) -

Philippe Cottagnoud,

Fernando Acosta,

M. Cottagnoud,

K Neftel,

Martin G. Täuber

Publication year - 2000

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.44.8.2179-2181.2000

Subject(s) - trovafloxacin , ceftriaxone , microbiology and biotechnology , penicillin , minimum inhibitory concentration , medicine , vancomycin , meningitis , antibiotics , antibacterial agent , pharmacology , streptococcus pneumoniae , biology , staphylococcus aureus , surgery , bacteria , genetics

The bactericidal activities of monotherapy with trovafloxacin (-0.37 +/- 0.15 Delta log(10) CFU/ml. h), vancomycin (-0.32 +/- 0.12 Delta log(10) CFU/ml. h), and ceftriaxone (-0.36 +/- 0.19 Delta log(10) CFU/ml. h) for the treatment of experimental meningitis in rabbits due to a clinical penicillin-resistant pneumococcal strain (MIC, 4 mg/liter) were similar. The combination of ceftriaxone with trovafloxacin considerably improved the killing rates (-0.67 +/- 0.16 Delta log(10) CFU/ml. h) and was slightly superior to ceftriaxone with vancomycin (killing rate, -0.53 +/- 0. 22 Delta log(10) CFU/ml. h), the regimen most commonly used in clinical practice. In vitro, synergy was demonstrated between ceftriaxone and trovafloxacin by the checkerboard method (fractional inhibitory concentration index, 0.5) and by time-killing assays over 8 h.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research